Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Immune checkpoint inhibitors (ICIs) have left a deep impression in the treatment of non-small cell lung cancer (NSCLC), however, not all patients benefit from it. The purpose of this study was to investigate the prognostic value of baseline bone mineral density (BMD) derived from chest computed tomography (CT) scans in NSCLC patients treated with ICIs.
Methods: This study included patients with advanced NSCLC who underwent ICI treatment at the Wuhan Union Hospital from March 2020 to October 2022. Baseline BMD was evaluated at non-contrast chest CT at the level of first lumbar vertebra. Patients were divided into BMD-lower group and BMD-higher group according to the optimal cutoff value calculated by X-tile software. Baseline characteristics of the two groups were compared and variables between the two groups were balanced by propensity score matching (PSM) analysis. We calculated the objective response rate (ORR) and disease control rate (DCR) of the two groups and analyzed overall survival (OS) and progression-free survival (PFS) using BMD and other clinical indexes through Cox regression models and Kaplan-Meier survival curves.
Results: A total of 479 patients were included in this study, and all patients were divided into BMD-lower group (n=270) and BMD-higher group (n=209). After PSM analysis, each group consisted of 150 patients. ORR (43.3% vs. 43.5% before PSM, = 0.964; 44.7% vs. 44.7% after PSM, = 1.000) and DCR (91.1% vs. 94.3% before PSM, = 0.195; 93.3% vs. 96.7% after PSM, =0.190) were similar in two groups. There was no statistically significant relationship between BMD degree and PFS before (16.0 months vs. 18.0 months, = 0.067) and after PSM analysis (17.0 months vs. 19.0 months, = 0.095). However, lower BMD was associated with shorter OS both before (20.5 months vs. 23.0 months, < 0.001) and after PSM analysis (20.0 months vs. 23.0 months, = 0.008).
Conclusion: Lower baseline BMD is associated with worse clinical outcomes in NSCLC patients treated with ICIs. As a reliable and easily obtained individual prognostic biomarker, BMD can become a routine detection indicator before immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11063287 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1332303 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.
Ann Surg Oncol
September 2025
Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.
Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.
KRAS mutations in Non-Small Cell Lung Cancer: translational aspects, current therapies and challenges for future research.
Crit Rev Oncol Hematol
September 2025
Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, 07100, Sassari, Italy; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy. Electronic address: gpalmier
Mutations in the KRAS gene are prominent oncogenic drivers in non-small cell lung cancer (NSCLC), with multiple pathophysiological, clinical and prognostic implications. Although historically considered an "undruggable" target, recent research led to the development of specific KRAS-G12C inhibitors, like sotorasib and adagrasib which are currently approved for clinical use in patients affected by advanced NSCLC. However, the clinical utility of these drugs is often limited by resistance development through several biological mechanisms, including additional KRAS mutations, activation of compensatory pathways and metabolic reprogramming.
View Article and Find Full Text PDFResponse to "Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients With Resectable NSCLC: Still an Open Question" by Dafni et al.
J Thorac Oncol
September 2025
Thoracic Surgery Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy; Tumor Immunology and Immunotherapy Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. Electronic address:
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.
ESMO Open
September 2025
Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.
Background: Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperative and adjuvant settings for resectable NSCLC and explore some controversial subgroups.
Materials And Methods: Systematic literature research was carried out for randomized controlled trials of neoadjuvant/perioperative chemo-immunotherapy or adjuvant immunotherapy for resectable NSCLC.
Survival outcomes of upfront versus delayed craniocerebral radiotherapy in EGFR-mutant NSCLC patients treated with third-generation EGFR-TKIs.
Clin Exp Metastasis
September 2025
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, China.